Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.50 |
| ▸ | MCHR2 | Q969V1 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719408 | 0.84 | HDAC3 (0.52) | HTR6MAPK14HTR2AHTR2C | |
| SCHEMBL6716133 | 0.84 | HTR6 (0.55) | HTR6MCHR1MCHR2MAPK14LTA4H | |
| SCHEMBL6763924 | 0.82 | KMT2A (0.52) | MCHR1MCHR2MAPK14LTA4H | |
| SCHEMBL3157146 | 0.82 | HTR6 (0.78) | HTR6 | |
| SCHEMBL6070000 | 0.82 | MCHR1 (0.71) | MCHR1MCHR2 | |
| SCHEMBL6711884 | 0.80 | HTR2A (0.48) | HTR6HTR2AHTR2C | |
| SCHEMBL6719936 | 0.79 | MAPT (0.54) | MCHR1MCHR2MAPK14LTA4H | |
| SCHEMBL18941044 | 0.78 | MCHR1 (0.49) | MCHR1LTA4H | |
| SCHEMBL6711939 | 0.78 | POLB (0.50) | MCHR1MCHR2MAPK14LTA4H | |
| SCHEMBL5862119 | 0.78 | MCHR1 (0.71) | MCHR1MCHR2MAPK14LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1555260-A | Aminoalkyl-substituted aromatic bicyclic compounds, process for their preparation and their use as pharmaceuticals | ���ĵ�˹ҩ��¹�����˾ | 2004-12-15 | — | — | CN | disclosed |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-30 | — | — | US | disclosed |
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212070-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR6 123/4885MCHR1 1689/4885MCHR2 1412/4885 |
| US-20040192693-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR6 123/4885MCHR1 1689/4885MCHR2 1412/4885 |
| US-20040198731-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR6 123/4885MCHR1 1689/4885MCHR2 1412/4885 |
| US-20040198733-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR6 123/4885MCHR1 1689/4885MCHR2 1412/4885 |
| US-20040198732-A1 | Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals | PER2, CNR2, DDC | HTR6 123/4885MCHR1 1689/4885MCHR2 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.